OLIGOMETASTATIC DISEASE AND SBRT:
THE SABR-COMET TRIAL
For patients with 1โ5 metastases, adding SBRT to systemic therapy nearly doubled 5-year survival in the SABR-COMET trial โ changing how oncologists approach limited metastatic disease.
analyticsAt a Glance
- check_circleSABR-COMET: 5-yr OS 42.3% (SBRT) vs 17.7% (standard care)
- check_circleApplicable across lung, breast, colorectal, and prostate primaries
- check_circleValidated for patients with 1โ5 oligometastases on modern imaging
- check_circleAvailable at leading centres in India and China
What Is Oligometastatic Disease?
Oligometastatic disease describes a limited number of metastatic deposits (typically 1โ5) in patients with otherwise controlled or minimal systemic disease burden โ a state considered potentially curable or at least durably controllable with local ablative therapy.
โOligometastatic disease sits between locally confined cancer and widespread metastatic spread โ a state where aggressive local therapy can change the trajectory of the disease.โ
Synchronous vs Metachronous
Synchronous oligometastases are present at initial diagnosis. Metachronous lesions appear during follow-up after initial treatment. Both can be addressed with SBRT, though metachronous patients often have better outcomes.
Metastasis-Directed Therapy
SBRT targets each individual metastasis with ablative precision โ eliminating all visible disease deposits while sparing normal tissue. Combined with systemic therapy, it aims to prolong progression-free and overall survival.
The SABR-COMET Trial: Design and Results
SABR-COMET was a randomised phase II trial conducted at 10 centres across four countries, enrolling patients with controlled primary tumours and 1โ5 oligometastases.
Trial Design
99 patients randomised 1:2 to standard-of-care (palliative intent) vs standard-of-care + SBRT to all metastatic lesions. Primary endpoint: overall survival. Included lung, liver, bone, lymph node, and adrenal metastases from breast, lung, colorectal, and prostate primaries.
Key Results
5-year OS: 42.3% (SBRT) vs 17.7% (standard care). Median OS: 50 months (SBRT) vs 28 months (control). PFS also significantly improved. Grade โฅ2 adverse events: 29% (SBRT) vs 9% (control) โ 4 treatment-related deaths in SBRT arm.
SABR-COMET 5-Year Outcomes
- 42.3%5-Year OS โ SBRT Armvs 17.7% in standard-of-care arm (SABR-COMET)
- 50 moMedian OS โ SBRT Armvs 28 months in standard care
- 2.4รOS ImprovementApproximate overall survival benefit from adding SBRT
- 29%Grade โฅ2 Toxicity (SBRT)Including 4 treatment-related deaths โ patient selection is critical
Who Is a Candidate for Oligometastatic SBRT?
Eligibility is determined by disease burden, primary tumour control, organ sites involved, and performance status.
| Criterion | Eligible | Requires Multidisciplinary Review |
|---|---|---|
| Number of metastases | 1โ3 lesions (strongest evidence) | 4โ5 lesions (SABR-COMET included up to 5) |
| Primary tumour status | Controlled or controlled on systemic therapy | Active primary with concurrent systemic treatment |
| Histology | Breast, lung, colorectal, prostate (best evidence) | Other histologies โ case-by-case |
| Prior systemic therapy | After standard lines of therapy | Treatment-naive oligometastatic โ discuss upfront strategy |
| Performance status | ECOG 0โ2 | ECOG 3 โ benefit uncertain |
Metastasis-Directed Therapy: Evidence by Tumour Type
Multiple histology-specific trials support SBRT in oligometastatic disease beyond SABR-COMET.
Supporting Trial Evidence by Tumour Type
- Prostate (STOMP trial โ ADT-free survival)HR 0.41
- Lung (SINDAS โ PFS benefit with SBRT)Sig. PFS benefit
- Colorectal (OMIT โ LC >90% per lesion)90% LC
- Breast (CURB โ accruing)Phase II ongoing
Adding SBRT to Systemic Therapy: Risks and Benefits
Careful patient selection is essential โ the SABR-COMET arm had 4 treatment-related deaths, emphasising that SBRT in oligometastatic disease requires experienced, multidisciplinary teams.
Potential Benefits
- Significant OS improvement (SABR-COMET)5-yr OS 42.3% vs 17.7% โ one of the largest metastatic cancer survival signals from SBRT
- Delays systemic therapy escalationControlling all visible disease may extend time before next-line systemic therapy is needed
- Achieves local control at each siteIndividual lesion LC rates of 80โ95% with SBRT
- Applicable to multiple sitesLung, liver, bone, adrenal, lymph node โ all treatable with SBRT
Risks and Limitations
- Grade โฅ2 toxicity in 29% (SABR-COMET)Higher than systemic therapy alone โ careful dose planning required
- 4 treatment-related deaths in SABR-COMETHighlights importance of experienced centres and patient selection
- Does not eliminate occult micrometastasesSBRT treats visible disease; systemic therapy remains essential
- Limited to oligometastatic stateNot appropriate for patients with widespread metastatic disease burden
Explore More SBRT Topics
In-depth guides covering SBRT across cancer types and clinical scenarios.
Frequently Asked Questions
Oligometastatic SBRT
What is the maximum number of metastases that can be treated with SBRT?
The SABR-COMET trial enrolled patients with 1โ5 metastases, and this remains the most commonly cited eligibility threshold. Some centres apply a 3-lesion limit for the strongest evidence tier. The SABR-COMET 10 trial is investigating SBRT for patients with 4โ10 metastases, exploring whether the benefit extends to higher disease burden. Ultimately, eligibility is assessed on an individual basis considering lesion sites, cumulative dose constraints, and systemic disease control.
Does SBRT replace chemotherapy or immunotherapy in oligometastatic disease?
No. SBRT is added to standard-of-care systemic therapy โ not used in place of it. In SABR-COMET, both arms received systemic therapy; the experimental arm added SBRT on top. SBRT controls individual visible metastases; systemic therapy addresses micrometastatic disease that is not yet imageable. The two modalities are complementary.
Which cancer types have the best evidence for oligometastatic SBRT?
The highest-quality evidence currently exists for prostate cancer (STOMP, ORIOLE trials), non-small cell lung cancer (SINDAS trial), colorectal cancer (multiple phase II series), and broadly across histologies (SABR-COMET). Breast cancer has strong retrospective data with randomised trials ongoing (CURB). The approach is increasingly applied across all solid tumour histologies with oligometastatic presentation.
Is oligometastatic SBRT covered or accessible internationally?
SBRT for oligometastatic disease is available at academic cancer centres in India and China, often at significantly lower cost than in Western countries. Access requires a centre with experienced radiation oncology teams, modern linacs with IGRT capability, and multidisciplinary tumour board review. CancerFax can help identify appropriate centres, coordinate second opinions, and manage the logistics of international treatment access.
Can SBRT be repeated if new oligometastases develop?
Yes โ repeat SBRT for new oligometastatic lesions (termed "oligoprogression" management) is feasible and increasingly practiced. Each new lesion is evaluated independently for SBRT eligibility based on its site, size, and proximity to previously irradiated structures. Some patients have received multiple sequential courses of oligometastatic SBRT over several years, with maintained quality of life and delayed systemic therapy escalation.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Do You Have Oligometastatic Disease?
Upload your imaging and treatment history. Our team will assess whether SBRT-based metastasis-directed therapy is appropriate and connect you with experienced centres.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.